within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05A_AgentsForTreatmentOfHemorrhoidsAndAnalFissuresFo.C05AE02_IsosorbideDinitrate;

model IsosorbideDinitrate
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.25,
    Cl = 5.6666666666666664e-05,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0024,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01,
    Tlag = 0,
    Vdp = 0.00033,
    k12 = 6.833333333333333e-06,
    k21 = 6.833333333333333e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>IsosorbideDinitrate</td></tr><tr><td>ATC code:</td><td>C05AE02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.4</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Isosorbide dinitrate is an organic nitrate vasodilator used for the prevention and treatment of angina pectoris due to coronary artery disease. It acts by relaxing vascular smooth muscle via nitric oxide release, and has been used as an approved antianginal agent for decades.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Leier, CV (1985). Nitrate tolerance. <i>American heart journal</i> 110(1 Pt 2) 224–232. DOI:<a href=\"https://doi.org/10.1016/0002-8703(85)90491-0\">10.1016/0002-8703(85)90491-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3925742/\">https://pubmed.ncbi.nlm.nih.gov/3925742</a></p></li><li><p>Liu, Z, et al., &amp; Guo, R (2015). CGRP mediate the isosorbide-5-mononitrate cardiovascular response in healthy Chinese male volunteers through a XOR-independent pathway. <i>International journal of clinical pharmacology and therapeutics</i> 53(4) 325–334. DOI:<a href=\"https://doi.org/10.5414/CP202178\">10.5414/CP202178</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25740261/\">https://pubmed.ncbi.nlm.nih.gov/25740261</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C05AE02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end IsosorbideDinitrate;
